Today's Daily Dose brings you news about Alnylam Pharma's phase III ATLAS program for Fitusiran in patients with hemophilia A and B; Elite's pivotal bioequivalence fed study for reformulated immediate release version of SequestOx; Entellus' acquisition of privately-held Spirox and Inotek's disappointing results from phase II Fixed-dose Combination trial of Trabodenoson.
from RTT - Biotech http://ift.tt/2u85ZKK
via IFTTT
No comments:
Post a Comment